Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience - Top-Institutions - MDSpire

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • By

  • Fabian J. K. Allmendinger

  • Maximilian Deng

  • Sebastian Regnery

  • Lars Wessel

  • Katharina Kozyra

  • Felix Englert

  • Ricarda Wickert

  • Jannik Walter

  • Lucas Mose

  • Thomas Tessonnier

  • Sandro M. Krieg

  • Jürgen Debus

  • Laila König

  • Tanja Adena-Eichkorn

  • June 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLA

    Los Angeles, California

    Key Differentiators

    • Radiation Oncology

  • #2

    MARCAP Consortium
    MARCAP Consortium

    N/A, N/A

    Key Differentiators

    • Radiation Oncology

  • #3

    Heidelberg Ion Beam Therapy Center
    Heidelberg Ion Beam Therapy Center

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Radiation Oncology

  • #4

    UKHD Ethical Review Board
    UKHD Ethical Review Board

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Ethics in Research

  • #5

    Karolinska University Hospital
    Karolinska University Hospital

    Stockholm, Sweden

    Key Differentiators

    • Neurosurgery
    • Radiation Oncology

Original Source(s)

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • by Fabian J. K. Allmendinger, Maximilian Deng, Sebastian Regnery, Lars Wessel, Katharina Kozyra, Felix Englert, Ricarda Wickert, Jannik Walter, Lucas Mose, Thomas Tessonnier, Sandro M. Krieg, Jürgen Debus, Laila König, Tanja Adena-Eichkorn

  • June 12, 2026

Related Content

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice

The study points to a possible off-the-shelf cell therapy for solid tumors

  • June 16, 2026

  • 3 min
Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma